Versant Capital Management Inc Increases Stake in Fresenius Medical Care AG (NYSE:FMS)

Versant Capital Management Inc increased its position in shares of Fresenius Medical Care AG (NYSE:FMS) by 1,410.9% during the first quarter, according to its most recent Form 13F filing with the SEC. The firm owned 6,648 shares of the company’s stock after buying an additional 6,208 shares during the period. Versant Capital Management Inc’s holdings in Fresenius Medical Care were worth $166,000 at the end of the most recent reporting period.

Several other hedge funds have also recently added to or reduced their stakes in FMS. Smartleaf Asset Management LLC increased its position in shares of Fresenius Medical Care by 192.8% in the 4th quarter. Smartleaf Asset Management LLC now owns 1,224 shares of the company’s stock valued at $28,000 after purchasing an additional 806 shares during the last quarter. Russell Investments Group Ltd. raised its stake in Fresenius Medical Care by 234.1% in the fourth quarter. Russell Investments Group Ltd. now owns 3,151 shares of the company’s stock valued at $71,000 after buying an additional 2,208 shares in the last quarter. Jones Financial Companies Lllp lifted its holdings in Fresenius Medical Care by 80.5% during the 4th quarter. Jones Financial Companies Lllp now owns 4,510 shares of the company’s stock worth $102,000 after buying an additional 2,012 shares during the last quarter. Venturi Wealth Management LLC boosted its position in shares of Fresenius Medical Care by 8.4% during the 4th quarter. Venturi Wealth Management LLC now owns 5,700 shares of the company’s stock worth $129,000 after acquiring an additional 441 shares in the last quarter. Finally, Assetmark Inc. increased its holdings in shares of Fresenius Medical Care by 196.3% in the 4th quarter. Assetmark Inc. now owns 7,210 shares of the company’s stock valued at $163,000 after acquiring an additional 4,777 shares during the last quarter. Institutional investors and hedge funds own 8.37% of the company’s stock.

Fresenius Medical Care Stock Down 1.0%

Shares of NYSE FMS opened at $28.35 on Monday. The business has a 50-day moving average price of $25.96 and a 200 day moving average price of $24.31. The stock has a market cap of $16.64 billion, a PE ratio of 23.43, a price-to-earnings-growth ratio of 0.76 and a beta of 0.85. The company has a quick ratio of 1.02, a current ratio of 1.37 and a debt-to-equity ratio of 0.42. Fresenius Medical Care AG has a 52-week low of $17.93 and a 52-week high of $30.46.

Fresenius Medical Care (NYSE:FMS) last announced its earnings results on Tuesday, May 6th. The company reported $0.44 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.43 by $0.01. The business had revenue of $5.54 billion for the quarter, compared to analyst estimates of $4.71 billion. Fresenius Medical Care had a net margin of 3.43% and a return on equity of 6.04%. Equities research analysts forecast that Fresenius Medical Care AG will post 1.51 earnings per share for the current year.

Fresenius Medical Care Increases Dividend

The firm also recently disclosed an annual dividend, which will be paid on Friday, June 6th. Shareholders of record on Friday, May 23rd will be given a dividend of $0.7871 per share. This is an increase from Fresenius Medical Care’s previous annual dividend of $0.44. This represents a yield of 1.9%. The ex-dividend date of this dividend is Friday, May 23rd. Fresenius Medical Care’s dividend payout ratio (DPR) is presently 49.11%.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on the company. Morgan Stanley restated an “underweight” rating on shares of Fresenius Medical Care in a research note on Thursday, May 15th. Wall Street Zen initiated coverage on shares of Fresenius Medical Care in a research report on Tuesday, May 20th. They set a “strong-buy” rating for the company. Finally, Truist Financial increased their target price on shares of Fresenius Medical Care from $25.00 to $30.00 and gave the company a “hold” rating in a research report on Monday, May 12th. One research analyst has rated the stock with a sell rating, two have given a hold rating, one has issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the company has an average rating of “Hold” and a consensus target price of $27.80.

Fresenius Medical Care Company Profile

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.